HEMACORD - Cord Blood Transplant Therapy Approved by FDA

by Dr. Trupti Shirole on  November 12, 2011 at 12:13 AM Genetics & Stem Cells News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US FDA has now approved the first cord-blood transplant therapy- HEMACORD. Cord blood transplants are used for the treatment of blood cancer and certain inherited metabolic or immune system disorders.
 HEMACORD - Cord Blood Transplant Therapy Approved by FDA
HEMACORD - Cord Blood Transplant Therapy Approved by FDA

HEMACORD contains hematopoietic progenitor cells (HPCs) derived from human cord blood. When these HPCs are infused in the body, the cells transit to the bone marrow where they undergo division and maturation. As they circulate in the blood stream they can help build new blood cells or resurrect their working including immune function.

The cord blood treatment comprises a boxed warning related to risks of Graft Versus Host Disease(GVHD), engraftment syndrome, graft failure and infusion effects. This could also turn out to be fatal and therefore patients on HEMACORD should be inspected minutely.

HEMACORD is manufactured by the New York Blood Center (NYBC).

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Stem Cells - Cord Blood Thalassemia Stem Cells - Fundamentals Reiki and Pranic Healing Tissue Engineering and Regenerative Medicine Stem Cells Blood in Stools - Symptom Evaluation Bombay Blood Group 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive